Aug 21, 2015 | Recent Deals | Silicon Valley
Cooley advised GeneWEAVE Biosciences on its approximately $425 million sale to Roche.
GeneWEAVE is a privately-held in vitro diagnostics company that is advancing clinical microbiology with diagnostic solutions. It helps healthcare providers in the fight against drug-resistant bacteria by enabling impactful surveillance programs, early therapy guidance and successful antibiotic stewardship. Roche Molecular Diagnostics is a subsidiary of F. Hoffman-La Roche, the world’s largest biotech company.
The team advising GeneWEAVE included partners Mark Tanoury, Laura Medina and Barclay Kamb and associates Aaron Binstock, Kelsey Velemirovich and Carlton Fleming.
Related Posts:
- Cooley Represents Quickoffice in its Sale to Google
- Cooley Advises CHC Group on its $310 Million Initial Public Offering and Refinancing Transactions
- Cooley Advises ProteinSimple in $300 Million Sale to Techne Corporation
- Cooley Represents Molecular Partners in Broad Collaboration with Allergan
- Cooley Advises Jazz Pharmaceuticals plc on Rule 144A Offering of $575 Million of Exchangeable Senior Notes
